RUNX1 and breast carcinoma: Consistent with the bioinformatics analysis, the expression of RUNX2 was highest in the RUNX family in clinical breast cancer samples and cell lines; Moreover, RUNX2 was overexpressed, while RUNX1 and RUNX3 were decreased in breast cancer tissues (Fig. 1D, E).